Výsledky vyhledávání - "Marco A Chivalan"

Abstract P1-16-05: Oraxol + Encequidar (OPac+E) vs IV paclitaxel (IVPac) in the treatment of patients with metastatic breast cancer (mBC) (Study KX-ORAX-001): Subgroup survival analysis of patients with hepatic dysfunction

Autor: Gerardo Umanzor, Hope S Rugo, Francisco J Barrios, R H Vasallo, Marco A Chivalan, S Bejarano, Julio Roberto Ramirez, Luis Fein, R D Kowalyszyn, D L Cutler, D Kramer, H Wang, R MF Kwan

Publikováno v: Cancer Research. 82:P1-16

Background: IVPac is widely used to treat patients with breast cancer. oPac+E is oral paclitaxel in combination with Encequidar, an oral, minimally absorbed, specific p-glycoprotein inhibitor that enables the absorption of oral paclitaxel. Results of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d38383fb942a80deb271ccf0db35570
https://doi.org/10.1158/1538-7445.sabcs21-p1-16-05

Zobrazit plný text záznamu

Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer

Autor: Hope S, Rugo, Gerardo A, Umanzor, Francisco J, Barrios, Rosa H, Vasallo, Marco A, Chivalan, Suyapa, Bejarano, Julio R, Ramírez, Luis, Fein, Ruben D, Kowalyszyn, E Douglas, Kramer, Hui, Wang, Min-Fun R, Kwan, David L, Cutler

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 41(1)

PURPOSE Intravenous paclitaxel (IVpac) is complicated by neuropathy and requires premedication to prevent hypersensitivity-type reactions. Paclitaxel is poorly absorbed orally; encequidar (E), a novel P-glycoprotein pump inhibitor, allows oral absorp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41f1080421c72b6cc7509f5d3d50bf43
https://pubmed.ncbi.nlm.nih.gov/35858154

Zobrazit plný text záznamu

KX-ORAX-001: An open label, randomized, multicenter, phase III registrational study to determine the safety, tolerability, and tumor response of oraxol (HM30181A + oral paclitaxel) and its comparability to IV paclitaxel in patients with metastatic breast cancer (MBC)

Autor: T Moore, F J Barrios, Julio Roberto Ramirez Velasquez, Marco Antonio Chivalan Castro, Rosa Haydee Vassallo, David M. Cutler, Luis Fein, Douglas Kramer, Ruben Dario Kowalyszyn, Rudolf Kwan, J Goldfinch, Gerardo Antonio Umanzor Funez, Suyapa A. Bejarano

Publikováno v: Journal of Clinical Oncology. 37:TPS1116-TPS1116

TPS1116 Background: Paclitaxel is used in multiple cancer types including the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Due to poor oral absorpti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ff9d1fb7c9eaa89213e1d4a14957cbc3
https://doi.org/10.1200/jco.2019.37.15_suppl.tps1116

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání